XNAS
PEPG
Market cap166mUSD
Oct 08, Last price
2.38USD
1D
-0.83%
1Q
1.71%
IPO
-80.00%
Name
PepGen Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
13.52%
Rev. gr., 5y
%
Revenues
0
Net income
-90m
L-0.36%
CFO
-82m
L-0.89%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Key people
Independent Chairman of the Board · since 2021
Noel Donnelly
Chief Financial Officer · since 2021
Executive Vice President, Head of Research & Development · since 2024
Kasra Kasraian
Chief Technology Officer · since 2025
James McArthur
President, Chief Executive Officer, Treasurer, Secretary, Director · since 2021
Mary Delena
General Counsel, Company Secretary · since 2024
Mitchell Finer
Director · since 2025
Lisa Wyman
Director · since 2025
Independent Director · since 2022
Heidi Henson
Independent Director · since 2021
Independent Director · since 2023
Independent Director · since 2020
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||